LU91071I2 - Levodopa, carbidopa, entacapone (stalevo). - Google Patents

Levodopa, carbidopa, entacapone (stalevo).

Info

Publication number
LU91071I2
LU91071I2 LU91071C LU91071C LU91071I2 LU 91071 I2 LU91071 I2 LU 91071I2 LU 91071 C LU91071 C LU 91071C LU 91071 C LU91071 C LU 91071C LU 91071 I2 LU91071 I2 LU 91071I2
Authority
LU
Luxembourg
Prior art keywords
stalevo
entacapone
carbidopa
levodopa
product
Prior art date
Application number
LU91071C
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10665678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91071(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of LU91071I2 publication Critical patent/LU91071I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
LU91071C 1989-11-03 2004-04-09 Levodopa, carbidopa, entacapone (stalevo). LU91071I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8924838A GB2238047B (en) 1989-11-03 1989-11-03 Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation

Publications (1)

Publication Number Publication Date
LU91071I2 true LU91071I2 (fr) 2005-06-21

Family

ID=10665678

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91071C LU91071I2 (fr) 1989-11-03 2004-04-09 Levodopa, carbidopa, entacapone (stalevo).

Country Status (13)

Country Link
US (1) US5135950A (fr)
EP (1) EP0426468B1 (fr)
JP (1) JP2823680B2 (fr)
AT (1) ATE127447T1 (fr)
BR (1) BR1100289A (fr)
DE (2) DE122004000014I1 (fr)
DK (1) DK0426468T3 (fr)
ES (1) ES2075885T3 (fr)
FI (1) FI107149B (fr)
GB (1) GB2238047B (fr)
GR (1) GR3017526T3 (fr)
LU (1) LU91071I2 (fr)
NL (1) NL300147I1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB9113431D0 (en) * 1991-06-20 1991-08-07 Orion Yhytma Oy Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde
CA2080554A1 (fr) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Derives du styrene
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
ATE357453T1 (de) * 2003-12-19 2007-04-15 Hoffmann La Roche Comt-inhibitoren
AU2003296838A1 (en) * 2003-12-24 2005-08-11 Siddiqui Mohammed Jaweed Mukarram An efficient process for the manufacture of (e)-entacapone polymorphic form a
BR0318690A (pt) * 2003-12-29 2006-12-26 Wockhardt Ltd polimorfos estáveis de (e)-n,n-dietil-2-ciano-3-(3,4-dihidróxi-5-nitrofenil)acril amida
WO2005063696A2 (fr) * 2003-12-31 2005-07-14 Cilag Ag Nouvelles formes cristallines d'entacapone et fabrication
WO2005063695A1 (fr) * 2003-12-31 2005-07-14 Cilag Ag Nouvelles formes cristallines d'entacapone et leur production
EP1577289A1 (fr) 2004-03-18 2005-09-21 Revotar Biopharmaceuticals AG Inhibiteurs de selectine a petites molecules non glycosylees/glycosidiques/peptidiques pour le traitement de troubles inflammatoires
US20060003966A1 (en) * 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
US20080187590A1 (en) 2005-06-08 2008-08-07 Kari Vahervuo Oral Dosage Form
EP1901720A2 (fr) * 2005-06-23 2008-03-26 Spherics, Inc. Formes de dosage ameliorees pour le traitement de troubles moteurs
EP1764096A1 (fr) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux derivés de phloroglucinol ayant activité de ligande de selectine
EP1764093A1 (fr) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux composés aromatiques et leur application médical
EP1764095A1 (fr) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux derivés de nitrocatéchol ayant activité de ligande de selectine
WO2007054950A1 (fr) * 2005-11-09 2007-05-18 Usv Limited Procédé pour la préparation de (e)-n,n-diéthyl-2-cyano-3-(3,4-dihydroxy-5-nitrophényl)acrylamide (entacapone) extrêmement pur
EP1976824A1 (fr) * 2006-01-02 2008-10-08 Actavis Group PTC EHF Procede de preparation de la forme a de l'entacapone
EP1981840B1 (fr) * 2006-02-06 2012-04-18 Orion Corporation Procede de fabrication d'entacapone
WO2007094007A1 (fr) * 2006-02-13 2007-08-23 Suven Life Sciences Ltd., Procede ameliore de preparation de l'entacapone
WO2007113845A1 (fr) * 2006-04-03 2007-10-11 Alembic Limited Procédé de préparation de (e)-2-cyano-3-(3, 4-dihydroxy-5-nitrophényl)-n, n-diéthyl-2-propénamide (entacapone)
GB0610207D0 (en) * 2006-05-23 2006-07-05 Pliva Istrazivanje I Razvoj D New forms of active pharmaceutical ingredient
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20080004343A1 (en) * 2006-06-29 2008-01-03 Wockhardt Limited Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
GB0613826D0 (en) * 2006-07-12 2006-08-23 Pliva Istrazivanje I Razvoj D Process and product
ES2306587B1 (es) * 2006-11-15 2009-08-07 Quimica Sintetica, S.A. Nueva forma cristalina de entacapona y procedimiento para su obtencion.
ITMI20062450A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Procedimento per la preparazione di entacapone
WO2008079404A2 (fr) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentés
ES2319024B1 (es) * 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina.
WO2009084031A2 (fr) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Procédé amélioré de préparation de la forme polymorphe a du (2e)-2-cyano-3-(3,4-dihydroxy-5-nitrophényl)-n,n-diéthyl-2-propènamide
EP2251323B1 (fr) 2009-05-14 2014-04-23 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé de purification d'entacapone
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
CN103845317B (zh) 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (fr) 2013-10-07 2021-02-24 Impax Laboratories, LLC Formulations mucoadhésives à libération contrôlée de lévodopa et/ou d'esters de lévodopa et leurs utilisations
CN104402764A (zh) * 2014-11-26 2015-03-11 千辉药业（安徽）有限责任公司 一种恩他卡朋的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
EP0304493B1 (fr) * 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Derives d'hydroxystyrene
DE68917357T2 (de) * 1988-04-28 1995-01-26 Suntory Ltd Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
JP2535058B2 (ja) * 1988-07-29 1996-09-18 富士通株式会社 半導体装置の製造方法

Also Published As

Publication number Publication date
DE69022166T2 (de) 1996-02-15
EP0426468A3 (en) 1992-05-06
DE122004000014I1 (de) 2004-08-12
ATE127447T1 (de) 1995-09-15
NL300147I1 (nl) 2004-07-01
EP0426468B1 (fr) 1995-09-06
JPH03169844A (ja) 1991-07-23
EP0426468A2 (fr) 1991-05-08
US5135950A (en) 1992-08-04
GB2238047B (en) 1993-02-10
DE69022166D1 (de) 1995-10-12
GB8924838D0 (en) 1989-12-20
JP2823680B2 (ja) 1998-11-11
GR3017526T3 (en) 1995-12-31
BR1100289A (pt) 1999-10-05
ES2075885T3 (es) 1995-10-16
GB2238047A (en) 1991-05-22
FI107149B (fi) 2001-06-15
DK0426468T3 (da) 1995-10-23
FI905198A0 (fi) 1990-10-23

Similar Documents

Publication Publication Date Title
LU91071I2 (fr) Levodopa, carbidopa, entacapone (stalevo).
FR2710638B1 (fr) Procédé de préparation d'isomères d'acides benzènedicarboxyliques de haute pureté.
EP1048694A4 (fr) Composes azoiques et leur processus de production
NO912107L (no) Fortilsetning.
ATE188686T1 (de) Alkylierung von aminosäuren
AU7886287A (en) Aqueous coating composition and a process of coating a substrate with such coating composition
ATE129701T1 (de) Verfahren zur herstellung von flunixin und zwischenprodukten dafür.
EP0204555A3 (en) Method of producing an amide utilizing a microorganism
HU9602143D0 (en) Process for making hiv protease inhibitors
DE69002362D1 (de) Zusammensetzungen zur verhinderung des zusammenbackens von duengemitteln.
HUT60993A (en) Process for producing 2-chloro- and 2,6-dichloroaniline derivatives
JPS6425750A (en) Manufacture of 3,3-diarylacrylic acid amide
CA1273643C (fr) Procede pour la production de l'acide cis-2-methyl- 2-butenoique
DE59009505D1 (de) Verfahren zur herstellung von coilbreak-freiem warmband und alterungsbeständigem feuerverzinktem kaltband.
DK537789A (da) Fremgangsmaade til fremstilling af 3-chlor-2,4,5-triflourbenzoesyre
CA2271607A1 (fr) Procede pour stabiliser la cyanohydrine
DK680888A (da) Fremgangsmaade til fremstilling af dipeptider
White et al. A new synthesis of carboxylic acids from ketones
HUT45488A (en) Process for producing betaines
HUT37590A (en) Process for producing acyl-lactilates
PT1155138E (pt) Processo para a producao de derivados de acido 3,3,3-trifluorometil-2-alquilpropionico opticamente activos